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A B S T R A C T
Background
This review represents one in a family of three reviews focusing on the e-ectiveness of interventions in reducing drug use and criminal
activity for o-enders.
Objectives
To assess the e-ectiveness of interventions for female drug-using o-enders in reducing criminal activity, or drug use, or both.
Search methods
We searched 12 electronic bibliographic databases up to February 2019.
Selection criteria
We included randomised controlled trials (RCTs).
Data collection and analysis
We used standard methodological procedures expected by Cochrane.
Main results
We included 13 trials with 2560 participants. Interventions were delivered in prison (7/13 studies, 53%) and community (6/13 studies, 47%)
settings. The rating of bias was a-ected by the lack of clear reporting by authors, and we rated many items as 'unclear'.
In two studies (190 participants) collaborative case management in comparison to treatment as usual did not reduce drug use (risk ratio
(RR) 0.65, 95% confidence interval (CI) 0.20 to 2.12; 1 study, 77 participants; low-certainty evidence), reincarceration at nine months (RR
0.71, 95% CI 0.32 to 1.57; 1 study, 77 participants; low-certainty evidence), and number of subsequent arrests at 12 months (RR 1.11, 95%
CI 0.83 to 1.49; 1 study, 113 participants; low-certainty evidence).
One study (36 participants) comparing buprenorphine to placebo showed no significant reduction in self-reported drug use at end of
treatment (RR 0.57, 95% CI 0.27 to 1.20) and three months (RR 0.58, 95% CI 0.25 to 1.35); very low-certainty evidence. No adverse events
were reported.
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One study (38 participants) comparing interpersonal psychotherapy to a psychoeducational intervention did not find reduction in drug
use at three months (RR 0.67, 95% CI 0.30 to 1.50; low-certainty evidence).
One study (31 participants) comparing acceptance and commitment therapy (ACT) to a waiting list showed no significant reduction in self-
reported drug use using the Addiction Severity Index (mean di-erence (MD) -0.04, 95% CI -0.37 to 0.29) and abstinence from drug use at
six months (RR 2.89, 95% CI 0.73 to 11.43); low-certainty evidence.
One study (314 participants) comparing cognitive behavioural skills to a therapeutic community programme and aKercare showed no
significant reduction in self-reported drug use (RR 0.86, 95% CI 0.58 to 1.27), re-arrest for any type of crime (RR 0.73, 95% CI 0.52 to 1.03);
criminal activity (RR 0.80, 95% CI 0.63 to 1.03), or drug-related crime (RR 0.95, 95% CI 0.68 to 1.32). A significant reduction for arrested (not
for parole) violations at six months follow-up was significantly in favour of cognitive behavioural skills (RR 0.43, 95% CI 0.25 to 0.77; very
low-certainty evidence). A second study with 115 participants comparing cognitive behavioural skills to an alternative substance abuse
treatment showed no significant reduction in reincarceration at 12 months (RR 0.70, 95% CI 0.43 to 1.12; low certainty-evidence.
One study (44 participants) comparing cognitive behavioural skills and standard therapy versus treatment as usual showed no significant
reduction in Addiction Severity Index (ASI) drug score at three months (MD 0.02, 95% CI -0.05 to 0.09) and six months (MD -0.02, 95% CI
-0.09 to 0.05), and incarceration at three months (RR 0.46, 95% CI 0.04 to 4.68) and six months (RR 0.51, 95% CI 0.20 to 1.27); very low-
certainty evidence.
One study (171 participants) comparing a single computerised intervention versus case management showed no significant reduction in
the number of days not using drugs at three months (MD -0.89, 95% CI -4.83 to 3.05; low certainty-evidence).
One study (116 participants) comparing dialectic behavioural therapy and case management (DBT-CM) versus a health promotion
intervention showed no significant reduction at six months follow-up in positive drug testing (RR 0.67, 95% CI 0.43 to 1.03), number of
people not using marijuana (RR 1.23, 95% CI 0.95 to 1.59), crack (RR 1.00, 95% CI 0.87 to 1.14), cocaine (RR 1.02, 95% CI 0.93 to 1.12), heroin
(RR 1.05, 95% CI 0.98 to 1.13), methamphetamine (RR 1.02, 95% CI 0.87 to 1.20), and self-reported drug use for any drug (RR 1.20, 95% CI
0.92 to 1.56); very low-certainty evidence.
One study (211 participants) comparing a therapeutic community programme versus work release showed no significant reduction in
marijuana use at six months (RR 1.03, 95% CI 0.19 to 5.65), nor 18 months (RR 1.00, 95% CI 0.07 to 14.45), heroin use at six months (RR
1.59, 95% CI 0.49 to 5.14), nor 18 months (RR 1.92, 95% CI 0.24 to 15.37), crack use at six months (RR 2.07, 95% CI 0.41 to 10.41), nor 18
months (RR 1.64, 95% CI 0.19 to 14.06), cocaine use at six months (RR 1.09, 95% CI 0.79 to 1.50), nor 18 months (RR 0.93, 95% CI 0.64 to
1.35). It also showed no significant reduction in incarceration for drug o-ences at 18 months (RR 1.45, 95% CI 0.87 to 2.42); with overall
very low- to low-certainty evidence.
One study (511 participants) comparing intensive discharge planning and case management versus prison only showed no significant
reduction in use of marijuana (RR 0.79, 95% CI 0.53 to 1.16), hard drugs (RR 1.12, 95% CI 0.88 to 1.43), crack cocaine (RR 1.08, 95% CI 0.75
to 1.54), nor positive hair testing for marijuana (RR 0.75, 95% CI 0.55 to 1.03); it found a significant reduction in arrests (RR 0.19, 95% CI
0.04 to 0.87), but no significant reduction in drug charges (RR 1.07, 95% CI 0.75 to 1.53) nor incarceration (RR 1.09, 95% CI 0.86 to 1.39);
moderate-certainty evidence.
One narrative study summary (211 participants) comparing buprenorphine pre- and post-release from prison showed no significant
reduction in drug use at 12 months post-release; low certainty-evidence. No adverse e-ects were reported.
Authors' conclusions
The studies showed a high degree of heterogeneity for types of comparisons, outcome measures and small samples. Descriptions of
treatment modalities are required. On one outcome of arrest (no parole violations), we identified a significant reduction when cognitive
behavioural therapy (CBT) was compared to a therapeutic community programme. But for all other outcomes, none of the interventions
were e-ective. Larger trials are required to increase the precision of confidence about the certainty of evidence.
P L A I N   L A N G U A G E   S U M M A R Y
Interventions for female drug-using oenders
What is the aim?
To assess the e-ectiveness of interventions to reduce drug use, criminal activity, or both, in women involved in the criminal justice system.
What is the key message?
We are uncertain whether the treatments reduce subsequent drug use, criminal activity, or both. We identified too few studies to evaluate
whether the treatment
setting (for example, court or community) had an impact on the success of such programmes. The study sample sizes were small and the
certainty of this evidence was very low. High quality research is required to evaluate the e-ectiveness of di-erent treatment options.
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What was studied?
We studied any intervention aimed at reducing drug use, criminal activity, or both. Many more people involved in the criminal justice
system experience drug use compared to people who have no contact with the criminal justice system. Most of the interventions that are
used to support the rehabilitation of drug use in the criminal justice system are aimed at men and not women. Women have di-erent
needs to men and existing schemes need to be evaluated and adapted to deal with the complexity of the kinds of problems that women
experience in order to reduce female drug use, criminal activity, or both
What are the main results?
We found 13 trials including 2560 participants. The 13 trials included people who were assigned at random to one of two interventions,
conducted mainly in the USA. Studies were conducted in prison and the community. Study participants received a range of di-erent
interventions in comparison to nothing, another intervention or treatment as usual.
The review shows that:
- when women engage with collaborative case management, it may make little or no di-erence to reducing drug use, reincarceration or
rearrest in comparison to treatment as usual (low-certainty evidence);
- when women take buprenorphine, we are uncertain whether it reduces drug use in comparison to a placebo (very low-certainty evidence);
- when women take buprenorphine pre-release from prison, it may make little or no di-erence to reducing drug use or criminal activity in
comparison to taking buprenorphine post-release from prison (low-certainty evidence);
- when women engage with interpersonal psychotherapy, it may make little or no di-erence to reducing a relapse into drug use in
comparison to a psychoeducational intervention (low-certainty evidence);
- when women engage in acceptance and commitment therapy, it may make little or no di-erence to reducing drug use/ abstinence from
drug use in comparison to a waiting list control (low-certainty evidence);
- when women engage with cognitive skills in comparison to a therapeutic community intervention, we are uncertain whether it produces
a reduction in subsequent drug use, being rearrested, committing criminal activity or drug-related crimes (very low-certainty evidence);
- when women engage with cognitive skills in comparison to a therapeutic community intervention, it may reduce subsequent arrest (not
parole violations) (very low-certainty evidence);
- when women engage with cognitive skills in comparison to standard therapy, we are uncertain whether it reduces subsequent drug use
(very low-certainty evidence);
- when women engage with a single session of a computerised intervention, it may make little or no di-erence to reducing subsequent
drug use (low-certainty evidence) in comparison to face-to-face case management;
- when women engage with dialectic behavioural therapy and case management, we are uncertain whether it produces a reduction in
subsequent drug use in comparison to a health promotion scheme (very low-certainty evidence);
- when women engage in a therapeutic community programme, we are uncertain whether it reduces subsequent drug use and criminal
activity in comparison to a work release programme (very low- to low-certainty evidence);
- when women engage with intensive discharge planning upon release, it probably does not reduce subsequent drug use and criminal
activity in comparison to prison only (moderate-certainty evidence).
Funding sources were reported by all studies and included government and research/charitable foundations.
How up-to-date is this review?
February 2019.
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